MX2010009372A - Derivado heterociclico fusionado y su uso. - Google Patents
Derivado heterociclico fusionado y su uso.Info
- Publication number
- MX2010009372A MX2010009372A MX2010009372A MX2010009372A MX2010009372A MX 2010009372 A MX2010009372 A MX 2010009372A MX 2010009372 A MX2010009372 A MX 2010009372A MX 2010009372 A MX2010009372 A MX 2010009372A MX 2010009372 A MX2010009372 A MX 2010009372A
- Authority
- MX
- Mexico
- Prior art keywords
- optionally
- substituent
- ring
- fused heterocyclic
- heterocyclic derivative
- Prior art date
Links
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente invención proporciona un compuesto que tiene una actividad inhibidora de Smo superior y baja toxicidad, que es suficientemente satisfactoria como producto farmacéutico. La presente invención proporciona un compuesto representado por la fórmula (ver fórmula (I)) en donde anillo A es anillo de 5 a 7 miembros que esta opcionalmente sustituido, donde los sustituyentes están unidos opcionalmente entre sí para formar un anillo; X es O, S o NR1 (R1 es un átomo de hidrógeno o un grupo hidrocarburo que esta opcionalmente sustituido); R2 es carbamoilo que esta opcionalmente sustituido; y R3 es hidroxi que esta opcionalmente sustituido, o una sal del mismo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008045134 | 2008-02-26 | ||
| JP2008256755 | 2008-10-01 | ||
| PCT/JP2009/054007 WO2009107850A2 (en) | 2008-02-26 | 2009-02-25 | Fused heterocyclic derivative and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010009372A true MX2010009372A (es) | 2010-09-22 |
Family
ID=40905094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010009372A MX2010009372A (es) | 2008-02-26 | 2009-02-25 | Derivado heterociclico fusionado y su uso. |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8217176B2 (es) |
| EP (1) | EP2247588B1 (es) |
| JP (2) | JP4719317B2 (es) |
| KR (1) | KR101569949B1 (es) |
| CN (1) | CN102015705B (es) |
| AR (1) | AR070479A1 (es) |
| AU (1) | AU2009217982B2 (es) |
| BR (1) | BRPI0908417B1 (es) |
| CA (1) | CA2716773C (es) |
| CL (1) | CL2009000429A1 (es) |
| CO (1) | CO6321277A2 (es) |
| CR (1) | CR11661A (es) |
| DO (1) | DOP2010000260A (es) |
| EA (1) | EA020144B1 (es) |
| EC (1) | ECSP10010496A (es) |
| ES (1) | ES2586252T3 (es) |
| GE (1) | GEP20125664B (es) |
| IL (1) | IL207735A (es) |
| JO (1) | JO3259B1 (es) |
| MA (1) | MA32164B1 (es) |
| MX (1) | MX2010009372A (es) |
| MY (1) | MY150379A (es) |
| NZ (1) | NZ587719A (es) |
| PE (1) | PE20091556A1 (es) |
| TW (1) | TWI480282B (es) |
| WO (1) | WO2009107850A2 (es) |
| ZA (1) | ZA201006063B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101569949B1 (ko) * | 2008-02-26 | 2015-11-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 융합 헤테로시클릭 유도체 및 이의 용도 |
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| JPWO2011013752A1 (ja) * | 2009-07-31 | 2013-01-10 | 塩野義製薬株式会社 | 縮合へテロ環誘導体を含有する医薬組成物 |
| HRP20171755T1 (hr) | 2009-07-31 | 2017-12-29 | Grünenthal GmbH | Postupak kristalizacije i biološka raspoloživost |
| CN102574851A (zh) | 2009-08-26 | 2012-07-11 | 武田药品工业株式会社 | 稠合杂环衍生物及其用途 |
| US8927718B2 (en) | 2009-08-26 | 2015-01-06 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring derivative and use thereof |
| EP2471789B9 (en) * | 2009-08-26 | 2015-03-25 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring derivative and use thereof |
| WO2011024871A1 (ja) * | 2009-08-26 | 2011-03-03 | 武田薬品工業株式会社 | 縮合複素環誘導体およびその用途 |
| WO2012071517A2 (en) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
| WO2012154731A1 (en) * | 2011-05-08 | 2012-11-15 | Vanderbilt University | Substituted 1h-pyrrolo[3,2-c]quinolin-4(5h)-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| WO2013170115A1 (en) | 2012-05-11 | 2013-11-14 | Abbvie Inc. | Pyridazine and pyridine derivatives as nampt inhibitors |
| DK3077544T3 (da) * | 2013-12-03 | 2019-07-08 | Celestra Life Science Llc | Rationelt-baseret design af en målrettet terapi til cancer |
| WO2015140964A1 (ja) | 2014-03-19 | 2015-09-24 | 株式会社 東芝 | 電池用電極材料、非水電解質電池及び電池パック |
| EP3127907A4 (en) * | 2014-03-31 | 2018-04-04 | Boston Biomedical, Inc. | New tricyclic quinone derivative |
| CN107709314A (zh) | 2015-06-11 | 2018-02-16 | 巴斯利尔药物国际股份公司 | 外排泵抑制剂及其治疗性用途 |
| AU2015101598A4 (en) * | 2015-09-17 | 2015-12-03 | Macau University Of Science And Technology | Novel ros1 inhibitor and its use |
| ES2902513T3 (es) * | 2016-02-01 | 2022-03-28 | Takeda Pharmaceuticals Co | Cocristal |
| US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
| US11299469B2 (en) | 2016-11-29 | 2022-04-12 | Sumitomo Dainippon Pharma Oncology, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| JP7091201B2 (ja) | 2018-09-14 | 2022-06-27 | 株式会社東芝 | 活物質、電極、二次電池、電池パック、及び車両 |
| RU2711968C1 (ru) * | 2018-11-22 | 2020-01-24 | федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский национальный исследовательский политехнический университет" | Анальгезирующее средство |
| KR20220002745A (ko) * | 2019-05-29 | 2022-01-06 | 넬룸 코포레이션 | 암 치료 방법 및 용도 |
| CN110172068A (zh) * | 2019-06-05 | 2019-08-27 | 河南龙湖生物技术有限公司 | 具有抗肿瘤活性的苯并噻唑类化合物及其制备方法和应用 |
| JP7327855B2 (ja) | 2020-06-26 | 2023-08-16 | ラクオリア創薬株式会社 | レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬 |
| CN113292477B (zh) * | 2021-06-01 | 2023-06-02 | 四川大学 | 一种铱催化的碳氢活化反应合成异吲哚-1-酮类化合物的方法 |
| CN113429422B (zh) * | 2021-07-26 | 2022-05-10 | 中国人民解放军军事科学院军事医学研究院 | 一种噻吩并喹诺酮类化合物及其制备方法和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3012684B2 (ja) | 1989-12-08 | 2000-02-28 | 大日本製薬株式会社 | チエノキノリン誘導体、チエノナフチリジン誘導体およびそれらの塩 |
| AU3262593A (en) | 1992-01-11 | 1993-08-03 | Schering Agrochemicals Limited | Biheterocyclic fungicidal compounds |
| FR2695126B1 (fr) * | 1992-08-27 | 1994-11-10 | Sanofi Elf | Dérivés d'acide thiényl ou pyrrolyl carboxyliques, leur préparation et médicaments les contenant. |
| JP3223289B2 (ja) | 1992-10-22 | 2001-10-29 | 東洋アルミニウム株式会社 | 肉類調理器具および肉類調理方法 |
| WO1999062908A2 (en) | 1998-06-04 | 1999-12-09 | Abbott Laboratories | Cell adhesion-inhibiting antinflammatory compounds |
| HK1045306A1 (zh) | 1999-06-03 | 2002-11-22 | Abbott Laboratories | 抑制细胞黏附的抗炎化合物 |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| US7998986B2 (en) | 2001-12-21 | 2011-08-16 | Exelixis Patent Company Llc | Modulators of LXR |
| WO2004020599A2 (en) | 2002-08-29 | 2004-03-11 | Curis, Inc. | Hedgehog antagonists, methods and uses related thereto |
| JP2006151810A (ja) | 2002-12-26 | 2006-06-15 | Daiichi Asubio Pharma Co Ltd | ジヒドロチエノキノリン誘導体及びそれを含む細胞接着阻害剤 |
| US20050043346A1 (en) | 2003-08-08 | 2005-02-24 | Pharmacia Italia S.P.A. | Pyridylpyrrole derivatives active as kinase inhibitors |
| EP1671962A1 (en) | 2003-10-10 | 2006-06-21 | Ono Pharmaceutical Co., Ltd. | Novel fused heterocyclic compound and use thereof |
| EP1698335A4 (en) | 2003-12-26 | 2007-08-01 | Ono Pharmaceutical Co | AGENT FOR PREVENTING AND / OR TREATING DISEASES INVOLVING A MITOCHONDRIAL BENZODIAZEPINE RECEPTOR |
| US20070299102A1 (en) | 2004-04-08 | 2007-12-27 | Topo Target A/S | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| WO2007022268A2 (en) * | 2005-08-16 | 2007-02-22 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| AR056560A1 (es) * | 2005-10-06 | 2007-10-10 | Astrazeneca Ab | Pirrolopiridinonas como moduladores cb1 |
| DK1973910T3 (da) * | 2006-01-27 | 2013-08-12 | Shanghai Hengrui Pharm Co Ltd | Pyrrolo[3,2-c]pyridin-4-on-2-indolinon-proteinkinaseinhibitorer |
| KR20090006089A (ko) * | 2006-04-14 | 2009-01-14 | 노파르티스 아게 | 헤지호그 경로 관련 질환의 치료에서의 바이아릴카르복스아미드의 용도 |
| CN101679308B (zh) * | 2007-03-14 | 2014-05-07 | 埃克塞里艾克西斯公司 | Hedgehog途径抑制剂 |
| UA100684C2 (uk) * | 2007-03-15 | 2013-01-25 | Новартіс Аг | Похідні бензилу та піридинілу як модулятори сигнального шляху hedgehog |
| KR101569949B1 (ko) | 2008-02-26 | 2015-11-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 융합 헤테로시클릭 유도체 및 이의 용도 |
-
2009
- 2009-02-25 KR KR1020107021331A patent/KR101569949B1/ko active Active
- 2009-02-25 US US12/392,640 patent/US8217176B2/en active Active
- 2009-02-25 JP JP2010533355A patent/JP4719317B2/ja active Active
- 2009-02-25 AR ARP090100644A patent/AR070479A1/es active IP Right Grant
- 2009-02-25 CA CA2716773A patent/CA2716773C/en active Active
- 2009-02-25 US US12/919,413 patent/US8399449B2/en active Active
- 2009-02-25 JO JOP/2009/0079A patent/JO3259B1/ar active
- 2009-02-25 CN CN2009801148111A patent/CN102015705B/zh active Active
- 2009-02-25 MY MYPI2010004006A patent/MY150379A/en unknown
- 2009-02-25 EA EA201070994A patent/EA020144B1/ru unknown
- 2009-02-25 EP EP09714922.3A patent/EP2247588B1/en active Active
- 2009-02-25 GE GEAP200911952A patent/GEP20125664B/en unknown
- 2009-02-25 PE PE2009000279A patent/PE20091556A1/es active IP Right Grant
- 2009-02-25 ES ES09714922.3T patent/ES2586252T3/es active Active
- 2009-02-25 BR BRPI0908417-7A patent/BRPI0908417B1/pt active IP Right Grant
- 2009-02-25 NZ NZ587719A patent/NZ587719A/en unknown
- 2009-02-25 CL CL2009000429A patent/CL2009000429A1/es unknown
- 2009-02-25 MX MX2010009372A patent/MX2010009372A/es active IP Right Grant
- 2009-02-25 AU AU2009217982A patent/AU2009217982B2/en active Active
- 2009-02-25 TW TW098105923A patent/TWI480282B/zh active
- 2009-02-25 WO PCT/JP2009/054007 patent/WO2009107850A2/en not_active Ceased
-
2010
- 2010-08-22 IL IL207735A patent/IL207735A/en active IP Right Grant
- 2010-08-25 ZA ZA2010/06063A patent/ZA201006063B/en unknown
- 2010-08-26 DO DO2010000260A patent/DOP2010000260A/es unknown
- 2010-08-31 CR CR11661A patent/CR11661A/es unknown
- 2010-09-21 MA MA33195A patent/MA32164B1/fr unknown
- 2010-09-23 EC EC2010010496A patent/ECSP10010496A/es unknown
- 2010-09-23 CO CO10117653A patent/CO6321277A2/es active IP Right Grant
-
2011
- 2011-02-03 JP JP2011022188A patent/JP5490030B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO3259B1 (ar) | مشتق دائري مغاير ملتحم واستخدامه | |
| PH12016501822A1 (en) | Cyclopropaneamine compound | |
| MX2014000452A (es) | Derivados de azabencimiazol que tiene actividad activadora de la proteina cinasa activada monofosfato de denosina (ampk). | |
| PH12014501486A1 (en) | Novel nicotinamide derivative or salt thereof | |
| MY152972A (en) | Azabicyclo compound and salt thereof | |
| TNSN08407A1 (en) | Organic compounds | |
| MY160443A (en) | Nitrogen-containing heterocyclic compound and agricultural fungicide | |
| WO2008108378A3 (en) | Bicyclic oxomorpholine derivative | |
| WO2008108380A3 (en) | Pyrrole compounds | |
| WO2011004162A3 (en) | 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer | |
| MX2009007713A (es) | Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas. | |
| PH12016502358B1 (en) | Novel pyrrolidine compound and application as melanocortin receptor agonist | |
| WO2009057784A1 (ja) | 複素環化合物 | |
| WO2008156094A1 (ja) | ピリダジノン誘導体及びそれらを有効成分とするｐｄｅ阻害剤 | |
| TW200745034A (en) | New compounds | |
| MX2010008361A (es) | Derivados de arilamida oxazepinopirimidona sustituidos. | |
| GEP20125637B (en) | Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them | |
| MX2009008756A (es) | Compuesto macrociclico. | |
| MX2013007937A (es) | Nuevo derivado de indol o indazol o sal del mismo. | |
| TN2014000519A1 (en) | Pyrimidinone derivatives as antimalarial agents | |
| PL1877367T3 (pl) | Pochodne acetylenu | |
| MX2014002285A (es) | Inhibidores de la replicacion del vih. | |
| WO2009057733A1 (ja) | 血管新生阻害活性を有する新規インドール誘導体 | |
| WO2009069764A1 (ja) | オピオイド鎮痛剤 | |
| TN2010000381A1 (en) | Fused heterocyclic derivative and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |